Cooper Vision episode 1 (This panel discussion focuses on myopia management and how to make it simpler for practices and beneficial for patients. The experts discuss the importance of myopia management in reducing the risk of vision-threatening diseases and the standard of care in the field. They also highlight the MiSight daily soft contact lens as an effective tool for slowing the progression of myopia. The panelists share their approaches to identifying and treating myopic patients, emphasizing the importance of early intervention and preventive measures. The conversation provides valuable insights for practitioners looking to incorporate myopia management into their practices. In this conversation, the speakers discuss myopia management and the various treatment options available. They emphasize the importance of preventing myopia progression and the potential long-term consequences of untreated myopia. The speakers highlight the use of MiSight 1 day Soft Contact Lenses as the only FDA-approved treatment indicated to slow down myopia progression. They also discuss the importance of educating parents about the disease state and the benefits of myopia management. The speakers provide insights on setting fees and financial considerations, as well as transitioning patients from atropine to MiSight. They also address the question of when to stop myopia management and the availability of parameters for higher levels of myopia. The conversation concludes with tips on addressing sticker shock and the importance of training the entire team to effectively communicate with parents and provide comprehensive care.

--------------------------------

For our listeners, use the code 'EYECODEMEDIA22' for 10% off at check out for our Premiere Billing & Coding bundle or our EyeCode Billing & Coding course. Sharpen your billing and coding skills today and leave no money on the table!

Show Sponsors: CooperVision

https://coopervision.com/our-company/news-center/press-release/coopervision-and-aoa-join-forces-launch-myopia-collective